COMP <GO>
AMPH vs LLY // GROSS PROFIT MARGIN
Amphastar Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AMPH 4
— LLY 9
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $26.93 (+2.28%) • MKT CAP: $1.15B
gross-margins
49.50%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMPH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMPH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 49.50% | 83.64% | -34.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.00% | 32.36% | -23.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.4x | 36.4x | -27.02 | AMPH | /valuation <GO> |
| Free Cash Flow Yield | 10.58% | 2.30% | +8.28 | AMPH | /fcf-yield <GO> |
| Operating Margin | 19.50% | 40.21% | -20.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 13.60% | 31.90% | -18.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.70% | 45.51% | -47.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.47 | 9.29 | -6.82 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.8 | 66.6 | +0.24 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.9x | 26.3x | -15.35 | AMPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.15B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMPH REV | LLY REV | AMPH GROSS % | LLY GROSS % | AMPH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.9M | $65.18B | 49.5% | 83.0% | $121.2M | $16.81B |
| FY 2024 | $732.0M | $45.04B | 51.1% | 81.3% | $172.3M | $8.82B |
| FY 2023 | $644.4M | $34.12B | — | 79.3% | $183.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMPH // BETA —
LLY // BETA 0.51